Darren joined Polaris Partners in 2020 and is a managing partner in our Boston office. Darren currently represents Polaris on the boards of Noema Pharma, Tessa Therapeutics and August Bioservices.
Prior to joining Polaris, Darren completed a 22-year career with Eli Lilly and Company. As senior vice president of corporate business development he was responsible for all strategic transactions at Lilly, ranging from venture capital investments and acquisitions, to company formation and divestitures. Earlier, Darren reorganized and led the company’s venture capital operations and formed Lilly Ventures. He also founded and led Lilly Asia Ventures.
Darren was the founding CEO of InnoCentive, Inc., the first open-innovation company in the life sciences and now a part of Wazoku. He also led both corporate and new product development at RealMed, a healthcare transactions and technology company that is now part of Availity.
Darren earned an AB, masters in public administration, and juris doctorate from Syracuse University, where he was a University Scholar, University Fellow, L.E.S. Fellow, and Lehman Fellow.
The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.